| 產品名稱 |
Vaccinia virus ts mutant |
| 商品貨號 |
B187750 |
| Classification |
Poxviridae, Orthopoxvirus |
| Agent |
Vaccinia virus ts mutant |
| Strain |
IHD-W Dts66 |
| Applications |
Its mutation was assigned by complementation analysis (Lackner, et al, 2003) to map location A24, the 132-kDa viral RNA polymerase subunit. Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
Derived from IHD-W strain of vaccinia virus, which was derived from the IHD-J strain. |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
This conditional lethal mutant, originally designated plaque isolate no. 7954, was isolated from the IHD-W strain of Vaccinia by S. Dale after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine (Dales, et al, 1978). The non-permissive incubation temperature is 39.5°C. The mutant was not assigned to a Dales EM category. Its mutation was assigned by complementation analysis (Lackner, et al, 2003) to map location A24, the 132-kDa viral RNA polymerase subunit. Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Effect on Host |
Cytopathic effects in culture include enlargement and rounding of cells, followed by death and sloughing. CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium |
ATCC® Medium 30-2002: Dulbecco's Modified Eagle's Medium (DMEM)
Fetal Bovine Serum
|
| Recommended Host |
Recommended Host: ?BSC-40 (ATCC CRL-2761) Production host: BSC-40 (ATCC CRL-2761)
Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2 |
| Growth Conditions |
For best results, plate cells 24-48 hours in advance in DMEM with 10% FBS at 37.0°C. Infect at 90-100% confluence using a multiplicity of infection (MOI) of about 1. Infect and incubate in DMEM supplemented with 2% FBS at 32.0°C for 1-3 days. Harvest cells and culture fluids when 100% of culture shows advanced cytopathic effects. Vaccinia virus is largely cell associated. Concentrated preparations can be made by collection and sonication of cell pellets. |
| Name of Depositor |
S. Dales, R. Condit |
| References |
Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807
Condit RC, Motyczka A. Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus. Virology 113: 224-241, 1981. PubMed: 7269240
Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
|
